Which has better earnings and valuation, INMD or FOCL?

InMode has higher revenue and earnings than FocalTherics. FocalTherics is trading at a lower price-to-earnings ratio than InMode, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio InMode $370.49M 2.35 $93.83M $1.36 11.13 FocalTherics $70.53M 3.25 -$29.25M -$0.81 N/A

Is INMD or FOCL more profitable?

InMode has a net margin of 23.27% compared to FocalTherics' net margin of -41.47%. InMode's return on equity of 13.47% beat FocalTherics' return on equity. Company Net Margins Return on Equity Return on Assets InMode 23.27% 13.47% 11.95% FocalTherics -41.47% -137.61% -40.62%

Does the media prefer INMD or FOCL?

In the previous week, InMode had 1 more articles in the media than FocalTherics. MarketBeat recorded 5 mentions for InMode and 4 mentions for FocalTherics. InMode's average media sentiment score of 1.24 beat FocalTherics' score of 0.65 indicating that InMode is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment InMode 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive FocalTherics 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to AVR or FOCL?

In the previous week, Anteris Technologies Global had 18 more articles in the media than FocalTherics. MarketBeat recorded 22 mentions for Anteris Technologies Global and 4 mentions for FocalTherics. Anteris Technologies Global's average media sentiment score of 0.72 beat FocalTherics' score of 0.65 indicating that Anteris Technologies Global is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Anteris Technologies Global 14 Very Positive mention(s) 3 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive FocalTherics 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, SIBN or FOCL?

SiBone has higher revenue and earnings than FocalTherics. SiBone is trading at a lower price-to-earnings ratio than FocalTherics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio SiBone $206.22M 3.82 -$18.90M -$0.39 N/A FocalTherics $70.53M 3.25 -$29.25M -$0.81 N/A

Is SIBN or FOCL more profitable?

SiBone has a net margin of -8.10% compared to FocalTherics' net margin of -41.47%. SiBone's return on equity of -9.56% beat FocalTherics' return on equity. Company Net Margins Return on Equity Return on Assets SiBone -8.10% -9.56% -7.06% FocalTherics -41.47% -137.61% -40.62%

Does the media refer more to SIBN or FOCL?

In the previous week, SiBone had 4 more articles in the media than FocalTherics. MarketBeat recorded 8 mentions for SiBone and 4 mentions for FocalTherics. FocalTherics' average media sentiment score of 0.65 beat SiBone's score of 0.57 indicating that FocalTherics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SiBone 2 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive FocalTherics 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to SSII or FOCL?

In the previous week, SS Innovations International and SS Innovations International both had 4 articles in the media. SS Innovations International's average media sentiment score of 0.94 beat FocalTherics' score of 0.65 indicating that SS Innovations International is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SS Innovations International 2 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive FocalTherics 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer SGP or FOCL?

In the previous week, Spyglass Pharma had 1 more articles in the media than FocalTherics. MarketBeat recorded 5 mentions for Spyglass Pharma and 4 mentions for FocalTherics. FocalTherics' average media sentiment score of 0.65 beat Spyglass Pharma's score of 0.19 indicating that FocalTherics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Spyglass Pharma 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral FocalTherics 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

FocalTherics (FOCL) Competitors

$6.12 -0.02 (-0.33%)

As of 07/31/2026 04:00 PM Eastern

Compare

FOCL vs. INMD, AVR, SIBN, SSII, and SGP

Should you buy FocalTherics stock or one of its competitors? MarketBeat compares FocalTherics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with FocalTherics include InMode (INMD), Anteris Technologies Global (AVR), SiBone (SIBN), SS Innovations International (SSII), and Spyglass Pharma (SGP).

How does FocalTherics compare to InMode?

InMode (NASDAQ:INMD) and FocalTherics (NASDAQ:FOCL) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, risk, valuation, earnings, institutional ownership, analyst recommendations, profitability and media sentiment.

InMode has a beta of 1.89, meaning that its stock price is 89% more volatile than the broader market. Comparatively, FocalTherics has a beta of -0.04, meaning that its stock price is 104% less volatile than the broader market.

InMode has higher revenue and earnings than FocalTherics. FocalTherics is trading at a lower price-to-earnings ratio than InMode, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InMode	$370.49M	2.35	$93.83M	$1.36	11.13
FocalTherics	$70.53M	3.25	-$29.25M	-$0.81	N/A

68.0% of InMode shares are held by institutional investors. Comparatively, 62.7% of FocalTherics shares are held by institutional investors. 6.9% of InMode shares are held by company insiders. Comparatively, 10.1% of FocalTherics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, InMode had 1 more articles in the media than FocalTherics. MarketBeat recorded 5 mentions for InMode and 4 mentions for FocalTherics. InMode's average media sentiment score of 1.24 beat FocalTherics' score of 0.65 indicating that InMode is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
InMode	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
FocalTherics	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

InMode has a net margin of 23.27% compared to FocalTherics' net margin of -41.47%. InMode's return on equity of 13.47% beat FocalTherics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InMode	23.27%	13.47%	11.95%
FocalTherics	-41.47%	-137.61%	-40.62%

InMode currently has a consensus target price of $16.00, suggesting a potential upside of 5.68%. FocalTherics has a consensus target price of $9.00, suggesting a potential upside of 47.06%. Given FocalTherics' stronger consensus rating and higher possible upside, analysts clearly believe FocalTherics is more favorable than InMode.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InMode	1 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
FocalTherics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

Summary

InMode beats FocalTherics on 11 of the 16 factors compared between the two stocks.

How does FocalTherics compare to Anteris Technologies Global?

Anteris Technologies Global (NASDAQ:AVR) and FocalTherics (NASDAQ:FOCL) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, earnings, valuation, media sentiment, risk, analyst recommendations, profitability and institutional ownership.

FocalTherics has higher revenue and earnings than Anteris Technologies Global. FocalTherics is trading at a lower price-to-earnings ratio than Anteris Technologies Global, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anteris Technologies Global	$1.91M	399.55	-$94.14M	-$2.23	N/A
FocalTherics	$70.53M	3.25	-$29.25M	-$0.81	N/A

Anteris Technologies Global presently has a consensus price target of $16.00, suggesting a potential upside of 104.08%. FocalTherics has a consensus price target of $9.00, suggesting a potential upside of 47.06%. Given Anteris Technologies Global's stronger consensus rating and higher probable upside, analysts clearly believe Anteris Technologies Global is more favorable than FocalTherics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anteris Technologies Global	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
FocalTherics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

62.7% of FocalTherics shares are owned by institutional investors. 4.5% of Anteris Technologies Global shares are owned by company insiders. Comparatively, 10.1% of FocalTherics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Anteris Technologies Global had 18 more articles in the media than FocalTherics. MarketBeat recorded 22 mentions for Anteris Technologies Global and 4 mentions for FocalTherics. Anteris Technologies Global's average media sentiment score of 0.72 beat FocalTherics' score of 0.65 indicating that Anteris Technologies Global is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Anteris Technologies Global	14 Very Positive mention(s)	3 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
FocalTherics	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

FocalTherics has a net margin of -41.47% compared to Anteris Technologies Global's net margin of -5,148.78%. Anteris Technologies Global's return on equity of -124.76% beat FocalTherics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anteris Technologies Global	-5,148.78%	-124.76%	-101.21%
FocalTherics	-41.47%	-137.61%	-40.62%

Anteris Technologies Global has a beta of 1.79, suggesting that its stock price is 79% more volatile than the broader market. Comparatively, FocalTherics has a beta of -0.04, suggesting that its stock price is 104% less volatile than the broader market.

Summary

Anteris Technologies Global beats FocalTherics on 9 of the 17 factors compared between the two stocks.

How does FocalTherics compare to SiBone?

SiBone (NASDAQ:SIBN) and FocalTherics (NASDAQ:FOCL) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and media sentiment.

SiBone has higher revenue and earnings than FocalTherics. SiBone is trading at a lower price-to-earnings ratio than FocalTherics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SiBone	$206.22M	3.82	-$18.90M	-$0.39	N/A
FocalTherics	$70.53M	3.25	-$29.25M	-$0.81	N/A

SiBone has a net margin of -8.10% compared to FocalTherics' net margin of -41.47%. SiBone's return on equity of -9.56% beat FocalTherics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SiBone	-8.10%	-9.56%	-7.06%
FocalTherics	-41.47%	-137.61%	-40.62%

98.1% of SiBone shares are owned by institutional investors. Comparatively, 62.7% of FocalTherics shares are owned by institutional investors. 4.0% of SiBone shares are owned by insiders. Comparatively, 10.1% of FocalTherics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

SiBone currently has a consensus target price of $23.57, suggesting a potential upside of 32.72%. FocalTherics has a consensus target price of $9.00, suggesting a potential upside of 47.06%. Given FocalTherics' higher possible upside, analysts plainly believe FocalTherics is more favorable than SiBone.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SiBone	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
FocalTherics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

SiBone has a beta of 0.67, suggesting that its share price is 33% less volatile than the broader market. Comparatively, FocalTherics has a beta of -0.04, suggesting that its share price is 104% less volatile than the broader market.

In the previous week, SiBone had 4 more articles in the media than FocalTherics. MarketBeat recorded 8 mentions for SiBone and 4 mentions for FocalTherics. FocalTherics' average media sentiment score of 0.65 beat SiBone's score of 0.57 indicating that FocalTherics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SiBone	2 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
FocalTherics	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

SiBone beats FocalTherics on 12 of the 17 factors compared between the two stocks.

How does FocalTherics compare to SS Innovations International?

SS Innovations International (NASDAQ:SSII) and FocalTherics (NASDAQ:FOCL) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, media sentiment, risk, profitability, earnings and institutional ownership.

In the previous week, SS Innovations International and SS Innovations International both had 4 articles in the media. SS Innovations International's average media sentiment score of 0.94 beat FocalTherics' score of 0.65 indicating that SS Innovations International is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SS Innovations International	2 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
FocalTherics	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

62.7% of FocalTherics shares are owned by institutional investors. 10.1% of FocalTherics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

SS Innovations International has a net margin of -20.69% compared to FocalTherics' net margin of -41.47%. SS Innovations International's return on equity of -23.00% beat FocalTherics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SS Innovations International	-20.69%	-23.00%	-13.18%
FocalTherics	-41.47%	-137.61%	-40.62%

SS Innovations International presently has a consensus target price of $7.00, suggesting a potential upside of 75.88%. FocalTherics has a consensus target price of $9.00, suggesting a potential upside of 47.06%. Given SS Innovations International's higher possible upside, research analysts plainly believe SS Innovations International is more favorable than FocalTherics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SS Innovations International	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
FocalTherics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

SS Innovations International has a beta of -1.92, indicating that its stock price is 292% less volatile than the broader market. Comparatively, FocalTherics has a beta of -0.04, indicating that its stock price is 104% less volatile than the broader market.

SS Innovations International has higher earnings, but lower revenue than FocalTherics. SS Innovations International is trading at a lower price-to-earnings ratio than FocalTherics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SS Innovations International	$42.49M	18.75	-$12.13M	-$0.05	N/A
FocalTherics	$70.53M	3.25	-$29.25M	-$0.81	N/A

Summary

SS Innovations International and FocalTherics tied by winning 8 of the 16 factors compared between the two stocks.

How does FocalTherics compare to Spyglass Pharma?

Spyglass Pharma (NASDAQ:SGP) and FocalTherics (NASDAQ:FOCL) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, risk, valuation, profitability, institutional ownership and earnings.

In the previous week, Spyglass Pharma had 1 more articles in the media than FocalTherics. MarketBeat recorded 5 mentions for Spyglass Pharma and 4 mentions for FocalTherics. FocalTherics' average media sentiment score of 0.65 beat Spyglass Pharma's score of 0.19 indicating that FocalTherics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Spyglass Pharma	0 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
FocalTherics	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Spyglass Pharma has a net margin of 0.00% compared to FocalTherics' net margin of -41.47%. Spyglass Pharma's return on equity of 0.00% beat FocalTherics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spyglass Pharma	N/A	N/A	N/A
FocalTherics	-41.47%	-137.61%	-40.62%

Spyglass Pharma presently has a consensus price target of $45.00, suggesting a potential upside of 99.73%. FocalTherics has a consensus price target of $9.00, suggesting a potential upside of 47.06%. Given Spyglass Pharma's stronger consensus rating and higher probable upside, analysts clearly believe Spyglass Pharma is more favorable than FocalTherics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spyglass Pharma	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83
FocalTherics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

Spyglass Pharma has higher earnings, but lower revenue than FocalTherics. FocalTherics is trading at a lower price-to-earnings ratio than Spyglass Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spyglass Pharma	N/A	N/A	N/A	-$6.41	N/A
FocalTherics	$70.53M	3.25	-$29.25M	-$0.81	N/A

Summary

Spyglass Pharma beats FocalTherics on 8 of the 14 factors compared between the two stocks.

Get FocalTherics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FOCL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FOCL vs. The Competition

Export

Metric	FocalTherics	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$229.39M	$5.68B	$7.17B	$12.47B
Dividend Yield	N/A	1.79%	2.59%	10.03%
P/E Ratio	-7.56	23.11	282.25	24.53
Price / Sales	3.25	57.04	592.14	92.74
Price / Cash	N/A	32.53	28.60	46.71
Price / Book	11.77	6.31	10.93	6.07
Net Income	-$29.25M	$152.55M	$3.50B	$348.34M
7 Day Performance	1.49%	1.77%	-0.24%	0.09%
1 Month Performance	18.15%	4.58%	-3.70%	-5.17%
1 Year Performance	N/A	2.38%	61.98%	18.61%

FocalTherics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
FOCL FocalTherics	3.4455 of 5 stars	$6.12 -0.3%	$9.00 +47.1%	N/A	$229.39M	$70.53M	N/A	230	News Coverage Analyst Upgrade
INMD InMode	1.4814 of 5 stars	$15.45 +0.4%	$16.00 +3.6%	+10.2%	$887.79M	$374.64M	11.36	480	Positive News
AVR Anteris Technologies Global	2.2887 of 5 stars	$8.16 -0.1%	$16.00 +96.1%	+155.4%	$796.73M	$1.91M	N/A	138	News Coverage Positive News Insider Trade
SIBN SiBone	3.714 of 5 stars	$17.90 +5.0%	$23.57 +31.7%	+2.1%	$794.73M	$206.22M	N/A	350	News Coverage Upcoming Earnings Analyst Forecast
SSII SS Innovations International	1.6846 of 5 stars	$3.95 -0.4%	$7.00 +77.4%	-35.8%	$789.52M	$48.47M	N/A	4	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:FOCL) was last updated on 8/2/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

FocalTherics (FOCL) Competitors

FOCL vs. INMD, AVR, SIBN, SSII, and SGP

How does FocalTherics compare to InMode?

Summary

How does FocalTherics compare to Anteris Technologies Global?

Summary

How does FocalTherics compare to SiBone?

Summary

How does FocalTherics compare to SS Innovations International?

Summary

How does FocalTherics compare to Spyglass Pharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FOCL vs. The Competition

FocalTherics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

FocalTherics (FOCL) Competitors

FOCL vs. INMD, AVR, SIBN, SSII, and SGP

How does FocalTherics compare to InMode?

Which has more volatility and risk, INMD or FOCL?

Which has better earnings and valuation, INMD or FOCL?

Do insiders & institutionals hold more shares of INMD or FOCL?

Does the media prefer INMD or FOCL?

Is INMD or FOCL more profitable?

Do analysts recommend INMD or FOCL?

Summary

How does FocalTherics compare to Anteris Technologies Global?

Which has higher earnings & valuation, AVR or FOCL?

Do analysts recommend AVR or FOCL?

Do insiders & institutionals hold more shares of AVR or FOCL?

Does the media refer more to AVR or FOCL?

Is AVR or FOCL more profitable?

Which has more risk and volatility, AVR or FOCL?

Summary

How does FocalTherics compare to SiBone?

Which has preferable valuation & earnings, SIBN or FOCL?

Is SIBN or FOCL more profitable?

Do institutionals and insiders hold more shares of SIBN or FOCL?

Do analysts prefer SIBN or FOCL?

Which has more risk & volatility, SIBN or FOCL?

Does the media refer more to SIBN or FOCL?

Summary

How does FocalTherics compare to SS Innovations International?

Does the media refer more to SSII or FOCL?

Do insiders & institutionals hold more shares of SSII or FOCL?

Is SSII or FOCL more profitable?

Do analysts recommend SSII or FOCL?

Which has more volatility and risk, SSII or FOCL?

Which has preferable valuation and earnings, SSII or FOCL?

Summary

How does FocalTherics compare to Spyglass Pharma?

Does the media prefer SGP or FOCL?

Is SGP or FOCL more profitable?

Do analysts recommend SGP or FOCL?

Which has stronger earnings & valuation, SGP or FOCL?

Do institutionals and insiders hold more shares of SGP or FOCL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FOCL vs. The Competition

FocalTherics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools